ALIGOS THERAPEUTICS INC (ALGS)

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 67 full-time employees. The company went IPO on 2020-10-16. The firm discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. The company is also progressing oligonucleotide projects for MASH. The company is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Company Info

ALIGOS THERAPEUTICS INC

One Corporate Dr., 2Nd Floor, 2nd Floor

South San Francisco CALIFORNIA 94080

P: 18004666059

CEO: Lawrence M. Blatt

Employees: 67

Website: https://www.aligos.com/